Lisata Therapeutics granted US composition-of-matter patent for certepetide expiring 2040

LISATA THERAPEUTICS, INC.

U.S. Patent No. 12,351,653 covers certepetide's chemical structure and pharmacokinetic properties.
Patent expires March 2040 with opportunity for patent term extension.
CEO states strengthened IP estate and long-term market exclusivity for certepetide.
Patent includes claims for treating solid tumor cancers and methods of manufacture.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.